Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Recursion Pharmaceuticals In (RXRX)

334 + Investors. Track Smart Money conviction in RXRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +7
Streak
2Q ▲
Buyers last Q
58%

Smart Money Signals — RXRX

Based on 336 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added RXRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
336 hedge funds hold RXRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
〰️

Stable — ownership unchanged year-over-year

fund count last 6Q
The number of hedge funds holding RXRX is almost the same as a year ago (+1 funds, +0% change). No significant rush to buy or sell — institutional backing is holding steady.
🟡

Slight buying edge — 58% buying

193 buying140 selling
Last quarter: 193 funds bought or added vs 140 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-8 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 57 → 47 → 67 → 59. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

42% of holders stayed for 2+ years

■ 42% conviction (2yr+) ■ 34% medium ■ 24% new
141 out of 336 hedge funds have held RXRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares +1%, value -24%

Value
-24%
Shares
+1%
Last quarter: funds added +1% more shares while total portfolio value only changed -24%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📈

Growing discovery — still being found

67 → 57 → 47 → 67 → 59 new funds/Q
New funds entering each quarter: 57 → 47 → 67 → 59. A growing number of institutions are discovering RXRX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 49% veterans vs 28% newcomers

■ 49% veterans ■ 23% 1-2yr ■ 28% new
Entry-cohort mix of 348 holders: 172 (49%) are 2+ year veterans, 80 entered 1–2 years ago, and 96 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 35% AUM from major funds

35% from top-100 AUM funds
52 of 331 holders rank in the top 100 by AUM, accounting for 35% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — RXRX

In 2026 Q1, 193 hedge funds were net buyers of RXRX (59 opened a new position, 134 added to an existing one), while 140 reduced or exited (88 trimmed, 52 sold completely) — a 58% buyer ratio, indicating a slight buying edge. Net buying has persisted for two consecutive quarters, a positive momentum signal. 35% of total institutional value in RXRX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +7 funds (more new holders than closures). Total institutional holders: 336.

Hedge Fund Ownership: RXRX

How many hedge funds hold RXRX — quarterly history vs. share price
Quarterly hedge fund ownership of RXRX vs. share price

Market Analysis: RXRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: RXRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Recursion Pharmaceuticals In (RXRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much RXRX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
RXRX
+2.6%
XLV
+4.9%

RXRX outperformed XLV by -2.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
RXRX
+7.5%
XLV
+6.0%

Since the filing became public, RXRX outperformed XLV by +1.5% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

31 top-rated funds 2 high-conviction
Consensus
6.5
/ 10
breadth
×
Elite
3.2
/ 10
conviction
Hedge Fund Positioning: RXRX
334 + Investors

Track Smart Money conviction in RXRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 334 329 1.52%
13F Shares 342M 337M 1.48%
Total Value $1.04B $1.38B -24.2%
New Positions 57 67 -10
Increased Positions 131 122 +9
Closed Positions 52 58 -6
Reduced Positions 84 85 -1
Total Calls 12 9 33.33%
Total Puts 5 6 -16.67%
PUT/CALL Ratio 0.42 0.67 Bullish

Statistics: RXRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

334 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in RXRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 RXRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 DCVC Opportunity Fund II GP, LLC 87.48% 3,951,141 $12.1M
2 Data Collective IV GP, LLC 32.60% 5,941,120 $18.2M
3 MIC Capital Management UK LLP 8.40% 9,644,032 $29.6M
4 Nan Fung Group Holdings Ltd 1.51% 595,287 $1.8M
5 ARK Investment Management LLC 0.96% 40,212,769 $123.5M
6 Carroll Investors, Inc 0.84% 509,425 $1.6M
7 Pivotal bioVenture Partners Investment Advisor LLC 0.65% 595,518 $1.8M
8 IQ EQ FUND MANAGEMENT (IRELAND) Ltd 0.60% 2,557,403 $7.9M
9 Green Alpha Advisors, LLC 0.46% 152,098 $467K
10 Softbank Group CORP. 0.37% 13,636,515 $41.9M
11 Lingotto Investment Management LLP 0.36% 5,881,738 $18.1M
12 Amova Asset Management Americas, Inc. 0.23% 5,419,221 $16.6M
13 VARCOV Co. 0.20% 171,593 $527K
14 Headlands Technologies LLC 0.15% 427,839 $1.3M
15 Themes Management Co LLC 0.15% 77,000 $236K
16 Values First Advisors, Inc. 0.12% 74,236 $228K
17 Kieckhefer Group LLC 0.11% 74,000 $227K
18 Marathon Capital Management 0.10% 151,295 $464K
19 Allen Operations LLC 0.10% 217,657 $668K
20 Comprehensive Financial Management LLC 0.10% 941,895 $2.9M
21 Oxford Asset Management LLP 0.09% 71,753 $220K
22 Cherry Creek Investment Advisors, Inc. 0.09% 70,536 $217K
23 Baillie Gifford & Co 0.07% 23,675,407 $72.7M
24 Scientech Research LLC 0.07% 26,902 $83K
25 Havemeyer Place LP 0.07% 183,936 $565K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Recursion Pharmaceuticals In (RXRX)

What does the Smart Money Trend signal show for RXRX?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added RXRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for RXRX?

Slight buying edge — 58% buying: Last quarter: 193 funds bought or added vs 140 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for RXRX holders?

Strong quality — 35% AUM from major funds: 52 of 331 holders rank in the top 100 by AUM, accounting for 35% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held RXRX?

42% of holders stayed for 2+ years: 141 out of 336 hedge funds have held RXRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Recursion Pharmaceuticals In (RXRX) following the 2026 Q1 hedge fund 13F filings?

As of today, RXRX has moved +7.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of +1.5%. Since the quarter end (March 31, 2026), RXRX has gained +2.6% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →